Cordova Ashley
SEC CIK 1822014 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | Former CEO | 422.6K | $996.5K | $5.44M | 38 | 2021-07-06 | 2026-03-04 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
| 16 | Cordova Ashley | Former CEO | — | — |
Transactions 38
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | 2026-03-04 | NVCR | NovoCure Ltd | Cordova Ashley | Former CEO | F - Tax | $13.30 | -17.6K | 422.6K | -4% | -$234.6K | |
| 2026-03-03 | 2026-02-28 | NVCR | NovoCure Ltd | Cordova Ashley | Former CEO | A - Grant | $0.00 | +23.8K | 449.8K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | NovoCure Ltd | Cordova Ashley | Former CEO | F - Tax | $13.71 | -21.2K | 426.0K | -5% | -$290.4K |
| 2025-09-08 | 2025-09-05 | NVCR | NovoCure Ltd | Cordova Ashley | CEO | P - Purchase | $12.22 | +81.5K | 437.6K | +23% | +$996.5K | |
| 2025-07-01 | 2025-06-30 | NVCR | NovoCure Ltd | Cordova Ashley | CEO | A - Grant | $15.13 | +833 | 356.0K | +0.2% | +$12.6K | |
| D | 2025-03-06 | 2025-03-04 | NVCR | NovoCure Ltd | Cordova Ashley | CEO | A - Grant | $18.19 | +151.2K | 355.2K | +74% | +$2.75M |
| 2025-03-04 | 2025-03-03 | NVCR | NovoCure Ltd | Cordova Ashley | CEO | S - Sale | $18.54 | -2,053 | 204.0K | -1.0% | -$38.1K | |
| M | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Cordova Ashley | CEO | S - Sale | $19.72 | -13.5K | 210.2K | -6% | -$266.1K |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Cordova Ashley | CEO | S - Sale | $19.72 | -13.5K | 206.1K | -6% | -$266.1K |
| 2025-01-03 | 2024-12-31 | NVCR | NovoCure Ltd | Cordova Ashley | CEO | A - Grant | $14.75 | +373 | 219.6K | +0.2% | +$5,502 | |
| 2024-08-06 | 2024-06-28 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $12.24 | +1,286 | 220.5K | +0.6% | +$15.7K | |
| 2024-08-05 | 2024-08-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $20.14 | -688 | 219.2K | -0.3% | -$13.9K | |
| D | 2024-02-29 | 2024-02-27 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $16.30 | +102.2K | 219.9K | +87% | +$1.67M |
| DM | 2023-11-02 | 2023-10-31+ | NVCR | NovoCure Ltd | Cordova Ashley | CFO | M - OptEx | $9.60 | +18.0K | 109.7K | +20% | +$172.5K |
| 2023-09-05 | 2023-09-01 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $21.82 | -883 | 99.7K | -0.9% | -$19.3K | |
| 2023-08-04 | 2023-08-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $30.25 | -1,144 | 100.5K | -1% | -$34.6K | |
| 2023-07-06 | 2023-06-30 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $35.28 | +367 | 101.7K | +0.4% | +$12.9K | |
| M | 2023-03-07 | 2023-03-03 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $76.16 | -5,505 | 102.1K | -5% | -$419.3K |
| 2023-03-06 | 2023-03-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $75.28 | -1,055 | 95.0K | -1% | -$79.4K | |
| 2023-03-06 | 2023-03-03 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $0.00 | +11.8K | 106.8K | +12% | $0 | |
| D | 2023-03-02 | 2023-02-28 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $0.00 | +23.8K | 98.3K | +32% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $76.36 | -2,198 | 96.1K | -2% | -$167.8K |
| 2023-01-10 | 2023-01-06 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $62.31 | +66 | 74.4K | +0.1% | +$4,112 | |
| D | 2022-12-05 | 2022-12-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | M - OptEx | $7.15 | +2,000 | 74.4K | +3% | +$14.3K |
| 2022-09-06 | 2022-09-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $79.04 | -885 | 72.4K | -1% | -$70.0K | |
| 2022-08-03 | 2022-08-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $70.20 | +7,122 | 73.3K | +11% | +$500.0K | |
| 2022-07-07 | 2022-07-05 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $59.08 | +251 | 66.1K | +0.4% | +$14.8K | |
| DM | 2022-03-11 | 2022-03-03 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | M - OptEx | $14.61 | +5,040 | 64.7K | +8% | +$73.7K |
| 2022-03-09 | 2022-03-08 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $70.10 | -759 | 60.8K | -1% | -$53.2K | |
| D | 2022-03-07 | 2022-03-03 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $0.00 | +21.5K | 63.3K | +51% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $73.17 | -1,705 | 61.6K | -3% | -$124.7K |
| 2022-01-12 | 2022-01-06 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $63.82 | +46 | 41.8K | +0.1% | +$2,936 | |
| 2021-11-03 | 2021-11-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $107.28 | -209 | 41.8K | -0.5% | -$22.4K | |
| 2021-09-07 | 2021-09-02 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale | $138.23 | -828 | 42.0K | -2% | -$114.5K | |
| DM | 2021-08-16 | 2021-08-12 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | M - OptEx | $28.82 | +36.6K | 48.6K | +306% | +$1.06M |
| DM | 2021-08-16 | 2021-08-12 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | S - Sale+OE | $140.94 | -26.6K | 46.0K | -37% | -$3.75M |
| D | 2021-08-16 | 2021-08-12 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | G - Gift | $0.00 | -1,733 | 44.3K | -4% | $0 |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Cordova Ashley | CFO | A - Grant | $137.12 | +100 | 36.0K | +0.3% | +$13.7K |
Purchase Sale Sale after option exercise All abbreviations